Taggatz Stock Market Advisory – DOX, BVXV, FRG, AEMD
Mark Taggatz, CEO of Taggatz Stock Market Advisory provides commentary for NYSE and Nasdaq market stocks.
Amdocs was up $0.37
Amdocs Limited, through its subsidiaries, provides software and services to the communications, pay TV, entertainment, and media industry service providers worldwide. The company offers amdocsONE a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support, as well as consumer experience and monetization, media and digital, enterprise and connected society, service-driven network, and services and agile operation solutions.
BiondVax Pharmaceuticals (BVXV)
BiondVax Pharmaceuticals was up $1.32
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.
Franchise Group (FRG) set a new 52 week high by closing at $15.80 on Friday.
Franchise Group was up $8.50
Franchise Group, Inc., through its subsidiaries, provides tax preparation services in the United States and Canada. The company also facilitates refund-based tax settlement financial products, such as refund transfer products and personal income tax refund discounting, as well as provides an online digital Do-It-Yourself tax program in the United States.
Aethlon Medical (AEMD) set a new 52 week low by closing at $1.04 on Friday.
Aethlon Medical was down $0.96
Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals.
Disclaimer: The following information from Taggatz Stock Market Advisory is for informational purposes only and is not an offer to buy or sell securities. Taggatz Stock Market is not a FINRA broker-dealer or Registered Investment Advisor. Taggatz Stock Market advisory does not own stock in any of the companies mentioned in this release. Taggatz Stock Market Advisory has not been paid by any of the companies mentioned in this release.